August 29, 2024 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Advance Care Planning (ACP).
MIPS Quality Measures Dashboard
The dashboard has been updated to include a new measure, MIPS #134 CQM version: Preventive Care and Screening: Screening for Depression and Follow-Up Plan, as detailed below. This is the registry version of the measure.
Historically, the MIPS #134 eCQM (EHR version) has been live on the MIPS Quality Dashboard. Due to substantive changes to the eCQM, there is no CMS National Benchmark for 2024. Therefore, to give practices the option to report the depression measure to guarantee that there will be associated MIPS performance scores, Practice Insights has added the MIPS CQM (registry version) to the dashboard.
Practices can submit data on either version of the measure for 2024, or even both, and CMS will use the higher score of the two for performance purposes. If a significant number of participants submit the eCQM version of the measure in 2024, CMS may issue same-year benchmarks.
| Measure | Description | |
|---|---|---|
| MIPS #134 CQM version: Preventive Care and Screening: Screening for Depression and Follow-Up Plan | A percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days before the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented in the visit note and shared with the patient on the date of the visit or up to two days after the date of the qualifying encounter. | Numerator: Number of patients screened for depression on the date of the encounter or up to 14 days before the date of the encounter using an age-appropriate standardized tool.
Denominator: All patients aged 12 years and older at the beginning of the measurement period with at least one qualifying encounter during the measurement period. Exclusions: Patients diagnosed with bipolar disorder at any time before the qualifying encounter. |
Advance Care Planning Performance Dashboard
Previously, when users clicked on any data point within the % with any Hospice Enrollment column, the dashboard failed to populate with the corresponding list of patients. This has been resolved, and now, selecting any data point in the column will display the patient list as expected.
Status of Dashboard Updates for 2024
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2024 requirements. The measures listed below either have no 2024 update required or have been updated.
| Measure | Description |
|---|---|
MIPS Quality Measures Dashboard |
|
| #128 | BMI (This measure is no longer a MIPS Traditional Measure) |
| #130 | Current Medications |
| #134 (eCQM Version) | Preventive Care and Screening for Depression and Follow-Up Plan |
| #134 (CQM Version) | Preventive Care and Screening for Depression and Follow-Up Plan |
|
#143 |
Pain Intensity Quantified |
| #374 | Closing the Referral Loop |
| #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
|
#487 |
Social Drivers of Health |
|
PIMSH#1 |
Advance Care Planning in Stage 4 Disease |
| PIMSH#2 | Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
| PIMSH#4 | Patient-Reported Pain Improvement |
| PIMSH#9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH#10 | Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
|
PIMSH#15 |
Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure) |
|
PIMSH#16 |
Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center |
